Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations

Abstract

Background and aims: Up till now the role of simeprevir plasma concentrations has not been described in treated patients affected by chronic hepatitis C and with dermatological side-effects. In this study, we have evaluated a possible relationship between plasma levels and the onset of skin complaints for the first time.

Methods: We report a clinical and pharmacokinetic analysis of 56 patients treated with simeprevir-based therapies.

Results: Simeprevir plasma concentrations were significantly related to dermatological side-effects at early time-points (P<0.001). In logistic regression, simeprevir concentrations at 1 week was the best predictive factor forskin symptoms (OR=1.901, 95%IC: 1.001-2.304; P=0.007).

Conclusion: Simeprevir plasma measurements could be a useful tool in a real-life clinical setting for prevention of dermatological symptoms.

Keywords: Dermatological side-effects; HCV; Pharmacokinetics; Simeprevir; Therapeutic drug monitoring.